Gut Microbiota–Derived Lipopolysaccharides and Short‐Chain Fatty Acids Regulate Immune Responses via FFAR2/FFAR3 in Lung Ischemia–Reperfusion Injury
Annals of the New York Academy of Sciences · 2025-11 · 1553 (1) · 449-460
DOI: 10.1111/nyas.70043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of the New York Academy of Sciences, 2025-10. Verfasst von Daisuke Maruyama und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Lipopolysaccharides, Reperfusion Injury, Receptors, G-Protein-Coupled, Fatty Acids, Volatile. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NHLBI NIH HHS, UCSF BCMM Trainee Pilot Award.
Abstract (Originalsprache)
Lung ischemia–reperfusion (IR) injury is a sterile inflammatory process seen in conditions such as hemorrhage‐resuscitation and pulmonary embolism. Our previous work suggests that alveolar macrophages (AMs) drive the inflammatory cascade via NLRP3 inflammasome activation, and that gut‐derived lipopolysaccharides (LPS) and short‐chain fatty acids (SCFAs) influence these responses. However, the precise mechanisms by which gut microbiota signals govern AM function during lung IR remain unclear. Here, we show that germ‐free mice exhibit reduced inflammatory responses compared to specific pathogen‐free mice following lung IR injury in vivo . In contrast, mice lacking free fatty acid receptor (FFAR)2 or FFAR3—receptors for SCFAs—display heightened inflammation relative to wild‐type controls. Ex vivo and in vitro nutritional IR experiments further demonstrate that AMs, primed with LPS, produce IL‐1 β via NLRP3 inflammasome and caspase‐1 activation. Notably, SCFAs significantly diminish IR‐induced IL‐1β release, indicating a protective effect. These findings support a gut–lung axis in which gut microbiota modulate baseline lung immune capacity or lung immune tone through the transmission of LPS and SCFAs, thereby shaping the lung's response to sterile injury. Gut microbiota–based therapies, including dietary fiber interventions, may thus represent a promising therapeutic strategy for regulating inflammatory processes in the lung.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, California, USA.
- Department of Anesthesiology, Sapporo Medical University School of Medicine, Sapporo, Japan.
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Illinois Chicago, Chicago, Illinois, USA.
- Department of Anesthesia and Perioperative Care, San Francisco General Hospital, San Francisco, California, USA.
ORCID-Profile: Daisuke Maruyama
Förderung
- NIH HHS
- NHLBI NIH HHS
- UCSF BCMM Trainee Pilot Award
- UCSF NORC
- NIGMS NIH HHS
- National Heart, Lung, and Blood Institute
- National Institutes of Health
Zitieren
APA
Maruyama, D., Doan, T. N. M., Tian, X., Chaki, T., Yeh, J. J., Layden, B. T., & Prakash, A. (2025). Gut Microbiota–Derived Lipopolysaccharides and Short‐Chain Fatty Acids Regulate Immune Responses via FFAR2/FFAR3 in Lung Ischemia–Reperfusion Injury. Annals of the New York Academy of Sciences, 1553(1), 449-460. https://doi.org/10.1111/nyas.70043
Vancouver
Maruyama D, Doan TNM, Tian X, Chaki T, Yeh JJ, Layden BT, et al. Gut Microbiota–Derived Lipopolysaccharides and Short‐Chain Fatty Acids Regulate Immune Responses via FFAR2/FFAR3 in Lung Ischemia–Reperfusion Injury. Annals of the New York Academy of Sciences. 2025;1553(1):449-460. doi:10.1111/nyas.70043
BibTeX
@article{Maruyama2025,
author = {Maruyama, Daisuke and Doan, Thien N M and Tian, Xiaoli and Chaki, Tomohiro and Yeh, Jade J and Layden, Brian T and Prakash, Arun},
title = {Gut Microbiota–Derived Lipopolysaccharides and Short‐Chain Fatty Acids Regulate Immune Responses via FFAR2/FFAR3 in Lung Ischemia–Reperfusion Injury},
journal = {Annals of the New York Academy of Sciences},
year = {2025},
volume = {1553},
number = {1},
pages = {449--460},
doi = {10.1111/nyas.70043}
}
EUVIMED